Current status of circulating tumor cell androgen receptor splice variant-7 in metastatic castration-resistant prostate cancer

Affiliations

Editorial

Shinichi Sakamoto. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S375.

doi: 10.21037/atm.2019.12.137.

¹ Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, Lu C, Rescigno P, Kolinsky M, Bertan C, Seed G, Riisnaes R, Miranda S, Crespo M, Pereira R, Ferreira A, Fowler G, Ebbs B, Flohr P, Neeb A, Bianchini D, Petremolo A, Sumanasuriya S, Paschalis A, Mateo J, Tunariu N, Yuan W, Carreira S, Plymate SR, Luo J, de Bono JS. Sharp A, et al. Eur Urol. 2019 Nov;76(5):676-685. doi: 10.1016/j.eururo.2019.04.006. Epub 2019 Apr 27. Eur Urol. 2019. PMID: 31036442

1. Annala M, Vandekerkhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov 2018;8:444-57. 10.1158/2159-8290.CD-17-0937 - DOI - PubMed
1. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38. 10.1056/NEJMoa1315815 - DOI - PMC - PubMed
1. Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 2017;35:2149-56. 10.1200/JCO.2016.70.1961 - DOI - PMC - PubMed
1. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402-18. 10.1200/JCO.2015.64.2702 - DOI - PMC - PubMed
1. Taplin ME, Antonarakis ES, Ferrante KJ, et al. Androgen receptor modulation optimized for response-splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer. Eur Urol 2019;76:843-51. 10.1016/j.eururo.2019.08.034 - DOI - PubMed